Catalpol (SKU N1352): Technical Guide for Disease Model Research

What This Product Solves

Catalpol (CAS No. 2415-24-9), also known as Catalpinoside, is a natural iridoid glycoside compound extracted from Rehmannia. Its primary research value lies in its established multi-target activity across several disease models, including neuroprotection, osteoporosis, ischemic stroke, and liver fibrosis. Catalpol modulates key signaling pathways such as NF-κB, EphA2/FAK/Src, NLRP3 inflammasome, TrkB, and VEGF-PI3K/AKT, enabling investigation of both anti-inflammatory and neuroprotective mechanisms. Researchers can leverage Catalpol in disease models where pathway-specific modulation is required, especially when modeling neurodegeneration, bone metabolism disorders, or fibrotic processes. It is not recommended for use in domains where its mechanism or dosing has not been established, as product-specific guidance is currently limited to the above areas.

For additional disease model context, the article Catalpol as a Multi-Pathway Modulator in Preclinical Research offers workflow-proven protocols, while Reliable Solutions in Neuroprotection Research addresses troubleshooting for neuroprotection and cytotoxicity assays.

Protocol Parameters

• In Vitro Assays (e.g., neuroprotection, cytotoxicity) | 2–100 μM | Recommended for cell-based studies including neuroprotection and inflammation models | Covers range validated for diverse cell types; enables titration to determine optimal dose | product information
• In Vivo Animal Models (e.g., osteoporosis, ischemic stroke, liver fibrosis) | 2.5–80 mg/kg/day | Applicable in disease models such as LPS-induced encephalopathy, ovariectomy-induced osteoporosis, permanent MCAO models, CCl4-induced liver fibrosis, and chronic unpredictable mild stress | Range reflects dose titration and model-specific requirements; select administration route and schedule per model | product information
• Compound Solubility | ≥17.47 mg/mL in ethanol (ultrasonic), ≥22.7 mg/mL in DMSO, ≥25.25 mg/mL in water | Critical for preparing dosing solutions for both cell culture and animal studies | Solubility options enable flexibility in vehicle choice based on downstream assay compatibility | product information

Workflow Setup and QC Checklist

• Compound Storage: Store Catalpol powder at -20°C, protected from light and moisture. Avoid repeated freeze-thaw cycles.
• Solution Preparation: Dissolve in water, DMSO, or ethanol according to solubility limits. Use ultrasonic assistance for ethanol dissolution. Prepare fresh solutions for each experiment to minimize degradation.
• Dose Optimization: Begin with recommended in vitro or in vivo ranges; optimize for cell type, model, and endpoint. Include vehicle-only controls.
• Administration Route: For in vivo studies, select the route (e.g., i.p., oral, i.v.) based on disease model and experimental design.
• QC Controls: Verify solution clarity and lack of particulates before use. Confirm final pH and osmolarity are compatible with biological systems.
• Documentation: Record lot number, preparation date, and storage conditions for all working solutions.

Common Failure Modes and Fixes

• Precipitation in Solution: If precipitation occurs in DMSO or ethanol, verify solubility thresholds and apply ultrasonic agitation. For water, ensure gradual addition of powder with stirring.
• Loss of Activity: Avoid storing diluted solutions for extended periods. Always prepare fresh working concentrations and minimize light exposure.
• Cell Toxicity at High Dose: In cell assays, titrate Catalpol concentration within the 2–100 μM range. Monitor cell health and adjust downward if cytotoxicity is observed in negative controls.
• Variability in Animal Model Outcomes: Ensure precise dosing and consistent administration schedules. Use validated animal models referenced in the product dossier for reproducibility.
• Inconsistent Results Across Batches: Use a single lot when possible within a study. Note lot-to-lot variation and include batch records in reporting.

Scope and Limitations

Catalpol is best suited for preclinical research in established models of neuroprotection, osteoporosis, ischemic stroke, and liver fibrosis, where its mechanisms and dosing parameters are documented. Application outside these domains, or in models lacking pathway homology, is not supported by current product data and should be undertaken with caution. The compound's multi-target activity requires careful control of experimental conditions and endpoint selection to avoid off-target confounds.

Long-term solution storage is discouraged due to potential degradation. Researchers should also consider possible solvent effects, especially when using high concentrations of DMSO or ethanol in sensitive assays. For mechanistic studies, Catalpol's pathway modulation should be validated within the context of each specific assay system.

Conclusion

Catalpol (SKU N1352) provides a technically validated tool for researchers modeling neuroprotection, osteoporosis, ischemic stroke, and liver fibrosis. Its multi-pathway modulation and compatibility with a range of assay systems make it versatile for preclinical workflows, provided protocols align with established solubility, dosing, and storage recommendations. For detailed product specifications and ordering, refer to the Catalpol product page at APExBIO. Internal articles linked above offer further workflow and troubleshooting detail specific to disease modeling applications.